U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230613) titled 'Neo-adjuvant Immunotherapy in Patients With Localized Melanoma' on Sept. 26.
Brief Summary: The success of anti-PD-1 and anti-CTLA-4 therapies has initiated a paradigm shift in oncology, with drugs now targeting the immune system rather than cancer cells to stimulate the antitumor immune response. Intratumoral (IT) delivery of immunostimulating agents reduces the systemic toxicity associated with monoclonal antibodies (mAbs) targeting immune checkpoints. Notably, IT injections of immune checkpoint blockade (ICB) have been shown to induce immune-mediated tumor responses both at the injected site and at distant, non-injected tumor sit...